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Abstract Stenosed segments of arteries significantly alter the blood flow known from healthy vessels. In particular, the wall shear
stress at critically stenosedarteries is at least an orderof magnitude higher than in healthy situations. This alteration repre-
sents a change in physical force and might be used as a trigger signal for drug delivery. Mechano-sensitive drug delivery
systems that preferentially release their payload under increased shear stress are discussed. Therefore, besides biological
or chemical markers, physical triggers are a further principle approach for targeted drug delivery. We hypothesize that
such a physical trigger is much more powerful to release drugs for vasodilation, plaque stabilization, or clot lysis at sten-
osed arteries than any known biological or chemical ones.
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1. Introduction
After a myocardial infarction or stroke, time is of utmost importance to
treat the patient successfully. Current technologies such as endovascu-
lar devices for intra-arterial clot lysis, stent implantation, or arterial
balloon dilatation are effective, but second-line, invasive treatments to
be performed in the operating theatre of the hospital. Nanomedicine
could offer approaches for non-invasive, rapid, monitoring-free, first-
line treatment as early as, for example, in the emergency vehicle, at pre-
hospital care, or in the emergency department and helps to further
reduce the morbidity and mortality of the world’s leading cause of
death. One potential candidate, tested in vitro, is a mechano-sensitive
liposome1 for targeting a culprit lesion in the case of an acute coronary
syndrome or stroke.
This article deals with recently proposed nanomedical approaches to
targeteddrugdelivery to treat cardiovasculardiseasesmoreefficiently. It
focuses on the mechanically driven drug release and, thus, covers the
definition of shear stress in cylindrical-shaped blood vessels and the
anatomy of atherosclerotic arteries. The liposome that responds to a
mechanical trigger, however, is the core of the review, as it is promising
for targeted drug delivery to treat acute or chronic cardiovascular
diseases.
Nanomedicine, the use of nanosciences and nanotechnology for the
benefit of patients, is an interdisciplinary approach to solve medical pro-
blems, where medical doctors closely work together with chemists,
biologists, and physicists to design nanoscale devices and treatment
methods for specific clinical needs. A typical field of nanomedical re-
search and first implementations is oncology. Here, for example, bio-
chemically tailored nanocontainers with target-specific moieties
locally fight a given disease.2,3
In cardiovascular use, targeting remains limited by the pathophysi-
ology of the core disease. Manifold processes including lipid accumula-
tion, inflammation, as well as muscular and fibrous tissue extension
followed by plaque calcification define atherosclerosis. Inflammatory
markers are found throughout the body,4 including in the human
artery tree.5 Since no disease-specific biomarker has been identified
for atherosclerosis so far, the challenge remains to discover an approach
that allows drug targeting to a symptomatic culprit lesion. A nanocontai-
ner targeting inflammatory markers could accidentally strike healthy
organs. Lanza et al.6 have reviewed the nanomedicine opportunities in
the field of cardiology, discussed approaches and limitations of biologic-
ally mediated targeting, and commented on the huge potential in future
clinical applications. As an example, angiogenesis-specific markers are
known.7 If one targets the blood vessel formation in tumours with sys-
temically administered therapeutics, there is also a risk to damage
healthy tissues, which require and benefit from angiogenesis. Such
drugs, which inhibit angiogenesis through vascular endothelial growth
factor, have been locally tested on ophthalmological diseases.8 By deli-
vering such formulations intravenously, one can successfully treat
cancer, although side-effects are described.9 Nonetheless, there are
existing approaches available for biochemical targeting of cardiovascular
disease. For example, perfluorocarbon nanoparticles (NPs) are in use
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for imaging of fibrin in unstable atherosclerotic plaques. Combined with
an anti-fibrin antibody, high magnetic resonance contrast is achieved,
which allows the detection of instable plaques with higher fibrin
content. Ruptured plaques can be identified with the paramagnetic
chemical exchange saturation transfer chelate technique for magnetic
resonance imaging.10 Glucose reduction in a capillary wall can theoret-
ically trigger nanocontainers to mark necrotic vascular tissue.11 Further-
more, anionic NPs could lower the cellular uptake of highly oxidized
low-density lipoprotein molecules.12 These approaches may lead to
an improved detection of instable plaque or vessels, where physiological
structures are broken down by atherosclerosis.
An approach to apply mechanical forces and their influence on ath-
erosclerosis physiopathology has to target the modified haemodynamic
conditions and flow variations specific for cardiovascular diseases. The
influence of mechanical conditions on vascular disease was discussed.
For example, Caro13 reviewed the available approaches exposing
more than a century of debates. He has concluded that wall shear
stress contributes mechanically to the development of atherosclerosis,
especially in low shear range regions. This discovery might contribute to
further understand a complex cascade of biomechanical physiopathol-
ogy of atherosclerosis. For a given flow, the wall shear stress is inversely
proportional to the vessel diameter.14 Unhealthy lowshear stress seems
to influence the balance between pro-atherogenic and anti-atherogenic
transcription factors and, thus, acts pro-atherogenically.15 Once plaque
develops, it alters the local haemodynamic flow condition and the shear
stress around the vessel stenosis significantly increases. In a lumen ob-
struction with 60% of the original diameter, the shear stress is four
times higher than in the normal vascular system.16 In a 80% stenosis, it
becomes more than 10 times higher.16 At arterial bifurcation and
aortic valves, a less prominent increase in wall shear stress is measured.17
The actual pathophysiological understanding of shear stress variation in
arteries were recently reviewed by Wentzel et al.18
2. Sections
2.1 Wall shear stress: mechanisms for
targeted drug delivery
Blood is regarded as a viscous fluid that moves along the vessel wall
(often considered as a solid boundary) and incurs a shear stress on
that wall. Under laminar flow conditions, which is usually a reasonable
assumption and results in a parabolic blood velocity profile (see
Figure 1), the shear stress t is expressed by the following:
t = 4hQ
pr3
,
whereh is the viscosity,Q the flowrate, and rdenotes the vessel radius.19
An even more detailed description is presented by Wellnhofer et al.20
The blood flow through a healthy artery generates a shear stress of
1 Pa. As the conservation of mass is valid within the blood vessel
system, constrictions (of the integrated cross section) result in an
increased velocity associated with higher shear stress (Figure 1). There-
fore, one observes shear stresses that are an order of magnitude
higher in stenosed vessels compared with healthy ones. A heart
bypass can reduce the shear stress. This physical phenomenon can be
used to preferentially release drugs at stenosis taking advantage of
shear-stress-sensitive containers of sub-micrometer size.
2.2 Morphology of atherosclerosis
The anatomy of atherosclerotic plaques is well known and categorized
into six classes of severity, as defined by histological analysis.21,22
The histological determination of tissue type and biochemical character-
ization is a routine procedure.However, in contrast to in vivo angiograph-
ic images, the tissue morphology is captured in the postmortem state and
altered during numerous preparation steps including the embedding.23
In vivo magnetic resonance, computed tomography, and angiography
give rise to images representing physiological conditions, i.e. without
tissue deformations and shrinkage, which are generated when preparing
the histological slices. The currently available spatial resolution of in vivo
imaging techniques, however, does not reach the micrometer precision
necessary for quantitative conclusions derived from flow simulations.
Local flow simulations confirm the presence of significantly enhanced
shear stresses around the stenosis site. It should be noted that the
wall shear stress significantly increases before the actual stenosis
starts, which can be either explained geometrically via a funnel-like nar-
rowing entrance to the stenosis or dynamically via the transition from
laminar to turbulent flow. A mechano-sensitive drug delivery nanocon-
tainer is, therefore, triggered before its passage through the stenosed
artery segment. As we do not know yet, how long it takes to release
the drug from the nanocontainer, the location of drug release can only
be a rough estimate. There are, however, phenomena, which drive the
drug towards the stenosis. First, the pulsatile flow makes sure that a
certain amount of nanocontainers and drugs stays close to the stenosis
for quite some time. Secondly, the fast diffusion of the drug in the vessel
walls24 ensures that a significant fraction of the drug will reach the sten-
osis. So far, drug release has in vitro been detected in a continuous flow
model, 4 cm after stenosis.1 In vivo, the blood flow velocity in normal
Figure 1 The arrows indicate the velocity profile of blood in cylin-
drically shaped vessels. The shear stress in the blood vessel is the spa-
tially dependent viscosity of blood h times the strain rate ∂2u/∂x∂y.
Near the vessel wall, the strain rate is simply the blood velocity
divided by the distance to the vessel wall or the tangent of the parabol-
oid at the wall (see upper scheme). Therefore, one uses, here, the term
wall shear stress. If the vessel has a constant diameter, the wall shear
stress is constant as well. At constrictions without bifurcation or
bypass, however, the blood velocity and, as a consequence, the wall
shear stress increases (see lower scheme).
Mechano-sensitive drug containers 329
coronary artery varies from 0 to 200 mm/s and, in a stenosed vessel, it
rises 600 mm/s.25,26 In a systolic–diastolic blood flow, a near flow-
stopwill contribute to the increaseof the free drug’s residence time. Fur-
thermore, reflow phenomena are high around a stenosis, which should
counteract the effect of rapid passage through the stenosis.27 With both
the reflow phenomenon and the slow velocity during diastolic phase,
nanocontainers have an increased window of response time to release
their drug cargo at the targeted site, i.e. the stenosis of the arteries. Add-
itionally, the volume fraction of red blood cells and leucocytes appear to
be highest at intermediate shear stress values.28 A mathematical model
predicts an increase of flow resistance in zones of high wall shear
stress.29 The total shear-induced forces found in vivo could, therefore,
be even higher than predicted using the simplified models.
As to the morphology of the atherosclerosis, it should be mentioned
that the role of shear stress in its pathogenesis is well known, see, e.g.
Cunningham and Gotlieb.19 The wall shear stress acts on the endothelial
lining of the vasculature, which responds as a mechanotransducer30 and
induces the release of various substances including the vasodilator nitric
oxide. The formation of the stenosis is, therefore, not easy to under-
stand, although many phenomena are known in detail.
2.3 Mechano-sensitive drug containers for
targeted drug delivery
To take advantage of these atherosclerosis-specific blood flow varia-
tions, two approaches are currently presented: the use of mechano-
sensitive liposomes1 and shear stress-sensitive NPs aggregates.31
The first approach consists of an active compound encapsulated in
shear-stress-sensitive liposomes1 (Figure 2) that release their payload
at enhanced forces present near stenosis. The main clinical aim is a
prompt treatment after a myocardial infarction or stroke. Vesicles
made from an artificial 1,3-diamidophospholipid (Figure 3) are stable
under static conditions but release their contents at stenosed arteries.
These vesicles have a lenticular morphology. Along the equator, they
are less stable owing to the poorer ordering. In an idealized cardiovascu-
lar system replicated by polymer tubes (Figure 4) to simulate shear stress
to the vesicles in healthy and constricted vessels, drugs preferentially
release from the vesicles in constricted vessels. The proof-of-principle
is experienced on a model with isosmotic fluid and shows a nearly
30% increase of drug release in a critically stenosed vessel in comparison
with a normal one. Further investigations in more complex fluids and
animal tests are mandatory. The value of animal tests for conclusions
on the human body, however, is limited since the actual shear stress is
species-specific.14 Consequently, containers should be designed for a
generic human model, as animal results have to be interpreted with
caution. In spite of their difference to the human flow conditions,
animal tests are indispensable to better understand pharmacology of
the designed molecule from in vitro tests and to proceed to toxicological
tests there.
A second approach published is a shear-activated nano-therapeutic
aggregate (SANT) that breaks up into multiple smaller NPs in a high
shear stress environment. The goal is to treat vessel clots such as pul-
monary embolism.31 The SANTs are made from polylactic-co-glycolic
acid and form micrometer-sized aggregates composed of small
NPs. Pooled with endothelial cells and fibrin, these aggregates
stick better on the occluded vessels after shear-induced breaking. A
proof-of-principle experiment in a mouse model shows a survival rate
improvement of 86% of the shear-released tissue plasminogen activator
(tPA)-coated NP’s treated mice compared with the control group
(treated with the same dose of free tPA).
The intact aggregates are rapidly cleared from the bloodstream, i.e.
80% clearance during 5 min and due to their size similar to natural plate-
lets, i.e. 1–5 mm, no significant toxicity was found in the liver. The size of
the aggregates is tuneable. It will address various windows of shear stres-
ses between healthy and diseased tissues. The use of PEG polymers will
reduce any opsonization effects.
We have to state, however, that the aggregate particle approach is
somehow worrisome. These particles might be collected in the lungs,
but definitely be dispersed as they pass through the spleen, assuming
that they are not scavenged in an accelerated manner. It is clear that
only limited data are available at this point in time and that many chal-
lenges lie ahead until shear stress targeting will be available as a powerful
clinical tool, especially, if one follows the approach of Korin et al.31
2.4 Artificial mechano-sensitive liposomes
The phospholipid is a remarkable molecular arrangement frequently
found in nature. It contains a hydrophilic, i.e. water-attracting, head
and a hydrophobic, i.e. water-repelling, tail. At concentrations
,10212 M phospholipids associate into superstructures to minimize
the contact between bulk water and the hydrophobic parts of the mole-
cules.32 Depending of the actual chemical structure and the electrical
charge of the lipid, various geometrical arrangements have been
found, the most common ones, however, are the liposomes/vesicles,
spherulites containing a single or multiple closed concentric shells of
phospholipid bilayers around a small volume of an aqueous solution.33,34
The membrane enclosing the vesicle is chemically similar to that of the
Figure 2 Nanocontainers liberate an active drug at the critically
stenosed vessel because of the significantly increased wall shear stress.
Figure 3 Structure of the artificial 1,3-diamidophospholipid Pad–
PC–Pad.
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plasma membrane. The internal lumen, the hydrophilic surface, and the
hydrophobic membrane interior can be loaded with drugs. Such con-
structs are the fundament of currently available nanomedicine-based
drug delivery approaches in the clinics.35 Targeted release is passively
achieved using the enhanced permeability and retention (EPR) effect
and actively realized, for example tethering biomarkers to outer lipo-
some leaflet. They can increase the effective dose at the site of disease
by targeted delivery. Crystalized drugs inside the vesicle allow higher
dosages than could be delivered in vitro.36
The mean vesicle size and the vesicle size distribution can be con-
trolled during the formation process. Hence, the vesicle sizes can be
optimized for the intended clinical application. For the currently
known medical purposes, this size corresponds to a diameter of
100 nm. The liposomes are often coated with a layer of a protein-
repellent polymers.35 This modification allows the vesicle to escape
the opsonization and the rapid liver clearance. It stays in the blood circu-
lation for an extended period of time, a prerequisite for tumour-
targeting via the EPR effect taking advantage of leaky vasculature on
the periphery of a solid tumour.37 Such vesicles attracted much interest
and are present in the literature under the term ‘stealth liposomes’.
The standard vesicle has the spherical shape, which is the energy-
minimized morphology.32 Vesicles, however, belong to soft materials
as biological plasma membranes.38 Their bonding leads to intrinsic visco-
elastic properties and, more important, to metastable morphologies.
Nevertheless, vesicles are robust against lateral membrane disruption.
For example, following the reasonings of Bernard et al.39 it was found
that 100 nm liposomes formulated from natural lipids and surfactants
require shear stresses 40 Pa to disrupt their membranes. Since the
shear stress in a normal artery varies between 0.5 and 1.5 Pa, vs.
.13 Pa in a critically stenosed vessel, mechano-sensitive targeted
drug delivery cannot be achieved with such natural lipid formulations.
Non-spherical vesicles, however, contain defects to adapt to the
changes in the membrane curvature. A lenticular vesicle, for example,
has a comparably high curvature around the equator and a rather low
curvature on the poles.40 Shear-induced deformation of the defect-
containing liposomes may result in transiently permeable membranes.
Bernard et al.39 discussed the shear-induced permeation and fusion of
lipid vesicles via a shear-induced, metastable, lentil-shaped state. They
combined cylindrically shaped lipids, which favour planar membranes,
and surfactants with conical shape, which tolerate rather high curva-
tures.33 In equilibrium, the surfactants are homogeneously distributed
in the vesicle. The application of shear stress induces surfactant cluster-
ing and changes the morphology from spherical to lentil shape. At the
cluster sites along the equator, pores are formed that allow the
content to escape. After the application of such a shear stress, the vesi-
cles relaxed back to their spherical morphology.
As a consequence, mechano-sensitive vesicles should have a lentil-
shaped morphology in the resting state, a feature that probably
increases the responsiveness of the system and leads to more rapid
release of the vesicle payload upon a shear trigger. It was, therefore,
surprising to observe that vesicles with a diameter of 100 nm formu-
lated from the artificial 1,3-diamidophospholipid Pad–PC–Pad
exactly exhibit the desired lentil-shaped morphology without the
need of having to add an additional lipid component (Figures 3 and
5).1 The application of shear stress should further attenuate
membrane-packing defects. This should lead to transient pore forma-
tion and leaking of liposome contents. The vesicles formulated from
1,3-diamidophosphocholines indeed showed rapid release of an en-
trapped fluorescent dye when the vesicles were shaken on a vortex
shaker. Without applying mechanical force, spontaneous release
was, however, avoided.
Figure 4 Cross-sectional area of a diseased (left) and healthy (right) artery model derived from microCT measurements. In the centre, 3D representa-
tions are given. From Holme et al.56
Figure 5 The cryo transmission electron microscopy micrograph
shows the lentil-shaped morphology of nanometer-sized vesicles in a
frame of 250 nm × 500 nm.
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Therefore, three categories of vesicles were identified, namely vesi-
cles that release their payload spontaneously and when shaken, vesicles
that do not release their payload either spontaneously or when shaken,
and vesicles that do not release their payload spontaneously but do so
when shaken. An example of the first category is a vesicle formulated
from egg phosphocholine. The second category is reached via formula-
tions from natural 16:0 sphingomyelin or dipalmitoyl phosphocholine.
The third category is formulated from the artificial phospholipid Pad–
PC–Pad.41
These recent findings on liposomes as containers are, however, not
the only ones, which describe the selective drug delivery to the site of
disease. Two prominent examples are already presented by Lasic42
and Adler-Moore and Proffitt43 .15 years ago.
3. Conclusion and clinical
perspectives
The clinical challenges in cardiovascular treatment strategies consist of
assuring the re-perfusionof the ischaemic-tissuecells within the shortest
period of time possible in order to prevent them from undergoing apop-
tosis. To achieve reperfusion at affected sites, bursts of maximal doses of
vasodilation, plaque-stabilizing (statins), and clot-lysing drugs are
required on the site of a ruptured plaque or the embolic clot responsible
for a myocardial infarction, ischaemic stroke, or pulmonary emboli. Sys-
temically administered, the desired therapeutic dose cannot be achieved
in such a short period of time. Systemically, administered drugs in the ne-
cessary doses have crucial side effects. A conventional targeted mechan-
ical approach requires a high-tech, in-hospital treatment by angiography
or surgical intervention and requires more time until the stenosis is spe-
cifically opened to enable normal blood flow restoration. To limit com-
plications, risk stratification protocols are studied and form the
foundations, e.g. of lysis guidelines for ischaemic stroke, myocardial in-
farction, and pulmonary embolism.44–46 Even following such a safer
treatment protocol, complications are observed.47,48 Moreover, they
limit the number of patients who can benefit of such a treatment or
limit the time window, within the treatment can be administered intra-
venously after symptoms begin for patients being statistically outside
the given security limits. For acute ischaemic stroke patients, for
example, intravenous clot lysis injection is allowed in a time window of
3–6 h after symptoms have begun. In-hospital door-to-needle time
aimed to be respected is proposed to be 1 h.49 But even then, side
effects persist with intracranial haemorrhage or clinical deterioration50
and patients not fitting to the general criteria cannot benefit from such a
treatment protocol. A more disease-specific approach is to carry the
active drugs with angiographic technologies to the occluded arterial
site. This technique needs special medical expertise and sophisticated
equipment and is also not denuded from potential side effects due to
angiography and catheterization (distant plaque embolization, arterial
wall dissection, bleeding, and renal insufficiency).51 –53 One limitation
of that technologyand to further investigate is the treatmentof complete
occluded vessels. In that case, no flow is permitted to pass. Although the
diffusion of the drug in the vessel walls can be fast,24 the drug has to be
present near the target. Some cardiologists may argue that it will be a mi-
nority of the cases as of heart attack, only 30% are of ST segment eleva-
tion myocardial infarction (STEMI) type with a whole occluded vessel54
and, in STEMI, underlying lesion seems not to be so occlusive55 as after
thrombus aspiration, 31% of culprit lesion is ,50% and 69% . 50%
occluded. Moreover, there is a spontaneous lytic phenomenon
permitting a partial recanalization allowing therapeutic success of this
technology. In vivo tests show therapeutic benefice for thrombolysis
with shear stress targeting drug delivery in a pulmonary embolism
mouse model.31
It is important to address the impact of washout on the effectiveness
of shear-stress-sensitive release. One example given above31 was tPA
release at local thrombotic partial occlusion leading to improved
mouse survival. Here, tPA is a fibrin-targeted molecule and its activity
depends on binding fibrin. For other drugs, almost all of which are not
targeted by nature, the local release will be followed by rapid washout
downstream. Therefore, the presented approach,1,31 which overcomes
the washout effect, is much more effective and of special interest. Shear
stress-sensitive drug vehicles might overcome the disadvantages of pro-
tocolled, risk-stratified systemic medical treatment strategies, the endo-
vascular device cure, or the minimal invasive or open surgical
approaches. Mechano-sensitive nanocontainers can even be admini-
strated at a pre-hospital level, depending on the disease condition.
This fire and forget nanoscale drug delivery is intended for a worldwide
easy, low-cost, and safe application field and a potential material to influ-
ence extensively the next step of limiting burden of disease and mortality
due to atherosclerosis. Today, the technology is an interesting idea, but
still nothing more. A huge amount of work has to be performed, before
the first patient might benefit from targeted drug delivery using
mechano-sensitive release from NPs or nanocontainers.
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